Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of CorMedix, Inc. (NYSE: CRMD) ("CorMedix" or "the Company"). The investigation concerns whether the Company violated specific sections of the Securities Exchange Act of 1934 by issuing materially misleading information to the investing public.

CorMedix is a pharmaceutical company, that intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. On June 29, 2015, published a report on CorMedix alleging, among other things, that: (1) CorMedix's only viable product in development is based on a 1970s-era chemical product acquired for less than $1 million in a bankruptcy sale; (2) CorMedix relies heavily on paid stock promoters to pump the stock's value; (3) CorMedix uses misleading clinical data to hide the fact that its Neutrolin/Taurolidine product is a failure; and (4) the Company is led by an alleged "wipeout artist," and associated with partners that have been barred from the securities business by FINRA. On this news, shares of CorMedix fell $0.81 per share, or 16%, to close on June 29, 2015 at $4.05 per share.

If you purchased Cormedix shares prior to June 29, 2015, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to, or visit our website at If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010